The U.S. FDA clearance Feb. 20 of East Windsor, N.J.-based Acrotech Biopharma Inc.’s PDE4 inhibitor Adquey (difamilast ointment 1%) for mild to moderate atopic dermatitis brought renewed focus on the mechanism, where other drugs are already approved and more are stocking developers’ pipelines across indications.

Researchers from Shanghai Ailux Biotechnology Co. Ltd. have disclosed preclinical data regarding their humanized bispecific antibody ALX-001 targeting TL1A and IL-23 for the potential treatment of immune-mediated inflammatory diseases (IMIDs).

After 118 years as a private company, dermatology specialist Leo Pharma A/S is poised to complete an IPO after reporting a full-year net profit for the first time since 2018.